大动脉炎手术与腔内治疗的效果及其影响因素

doi:10.3969/j.issn.1006-7795.2015.01.009

摘要/Abstract

摘要： 目的研究中国人种族中,大动脉炎腔内治疗及转流手术疗效的比较,以及影响因素的分析,为国人大动脉炎治疗方式的选择及术后合并症的预防提供数据参考.方法研究对象选取从2002年1月至2014年7月,在首都医科大学附属北京安贞医院血管科诊断为大动脉炎并进行外科治疗的患者,诊断标准采用1990年美国风湿病学会制定标准,对患者随访后进行数据分析.结果共行手术49例次,女性44例,占89.8%,平均发病年龄(27.20±10.35)岁,手术27例,腔内治疗22例(支架置入7例、球囊扩张15例),共处理病变血管61根.随访时间3~148个月,平均(50.43±42.708)个月,无死亡病例.通畅率方面,3个月通畅率97.8%,6个月通畅率95.6%,1年通畅率88.3%,3年通畅率79.6%,5年通畅率76.1%,10年通畅率57.1%.单纯球囊扩张成形术与球囊扩张＋支架置入术,1年通畅率分别为91.7%和68.6%(P=0.045).合并症方面,早期合并症仅有2例出血,晚期合并症共出现13例,其中脑梗死1例,血栓栓塞6例,再狭窄5例(支架内再狭窄2例,球囊扩张后再狭窄3例),人工血管排异反应1例,其中腔内治疗5例,转流手术8例(P=0.002).累计无合并症比率1年为88.1%,3年为79.0%,5年为75.4%,10年为51.9%.Logistic回归分析提示,随访期间免疫指标异常是术后合并症独立危险因素(OR=7.596,CI:1.091-52.884,P=0.041).结论转流手术与腔内治疗在3年和5年远期通畅率上,转流手术要明显优于腔内治疗;随访期间免疫指标的异常是术后出现合并症的独立危险因素,因此术后免疫调节显得尤为重要;球囊扩张成形术较球囊扩张加支架置入术有更好的一期通畅率.

关键词: 大动脉炎, 转流, 腔内治疗, 回顾性研究

Abstract: Objective This study aimed to compare endovascular treatment and bypass surgery for Takayasu ateritis(TA), to analyze influencing factors and to provide reference data for the treatment options of Takayasu arteritis and prevention of postoperative complications. Methods This is a retrospective review of patients with TA referred to us between 2002 and 2014. We used the American Rheumatism Association standards published in 1990 as diagnostic criteria.Results Total number of patients who received surgery was 49, including 44 female cases, accounting for 89.8%, the average age was (27.20±10.35) years, the bypass surgery was performed for 27 cases, endovascular treatment was given to 22 cases (7 cases received stent placement, 15 cases received percutaneous transluminal angioplasty, PTA), 61 culprit vessels were treated. The average follow-up period was (50.43±42.708) months (3-148 months), no deaths occurred. The primary patency rates for 3-month, 6-month, 1-year, 3-year, 5-year, 10-year were 97.8%, 95.6%, 88.3%, 79.6%, 76.1% and 57.1%, respectively. The PTA and stent placement, 1-year patency rates were 91.7% and 68.6% (P= 0.045). Only 2 cases had early complications of hemorrhage. Late complications occurred in a total of 13 cases, including 5 cases after endovascular treatment and 8 cases after bypass (P=0.002); Cerebral infarction in 1 case, thromboembolism in 6 cases, and restenosis in 5 cases (stent restenosis in 2 cases, 3 cases had restenosis after PTA), artificial vascular rejection occurred in 1 case. The overall 1-, 3-, 5-, 10-year no complication rates were 88.1%, 79.0%, 75.4% and 51.9%, respectively. The Logistic regression analysis showed that the immune abnormalities in follow-up period were independent risk factors for postoperative complications (OR: 7.596, CI: 1.091-52.884, P= 0.041). Conclusion Endovascular treatment was significantly superior to bypass surgery in terms of late complications; no significant difference was found between bypass surgery and endovascular treatment in long-term patency rate. Abnormalities in immune parameters during the period of follow-up may be independent risk factors of postoperative complications, postoperative immunomodulatory therapy may be particularly important. PTA had a better primary patency than stenting.

Key words: Takayasu arteritis, bypass, endovascular treatment, retrospective study

中图分类号:

R654.3

肖耀文, 陈忠, 杨耀国, 寇镭, 唐小斌, 吴章敏, 刘晖, 吴庆华. 大动脉炎手术与腔内治疗的效果及其影响因素[J]. 首都医科大学学报, 2015, 36(1): 45-52.

Xiao Yaowen, Chen Zhong, Yang Yaoguo, Kou Lei, Tang Xiaobin, Wu Zhangmin, Liu Hui, Wu Qinghua. Outcome and influencing factors of bypass and endovascular treatment for Takayasu arteritis[J]. Journal of Capital Medical University, 2015, 36(1): 45-52.

参考文献

[1] Numano F,Okawara M, Inomata H, et al. Takayasu's arteritis[J]. Lancet,2000,356(9234):1023-1025.
[2] Sugiyama K, Ijiri S,Tagawa S,el at.Takayasu disease on the centenary of its discovery[J].Jpn J Ophthalmol,2009,53(2):81-91.
[3] Jeeva I, Sajid J, Ali O, et al. Atypical Takayasu arteritis: a family with five affected siblings[J]. Med Sci Monit,2007,13(8):S101-S105.
[4] Terao C, Yoshifuji H, Ohmura K, et al. Association of Takayasu arteritis with HLA-B 67:01 and two amino acids in HLA-B protein[J]. Rheumatology(Oxford),2013,52(10):1769-1774.
[5] Lv N, Dang A, Wang Z, et al. Association of susceptibility to Takayasu arteritis in Chinese Han patients with HLA-DPB1[J]. Hum Immunol,2011,72(10):893-896.
[6] Lee S W, Kwon O J, Park M C, et al. HLA alleles in Korean patients with Takayasu arteritis[J]. Clin Exp Rheumatol,2007,25(1 Suppl 44):S18-S22.
[7] Kerr G S, Hallahan C W, Giordano J, et al. Takayasu arteritis[J]. Ann Intern Med,1994,120(11):919-929.
[8] Ohigashi H, Haraguchi G, Konishi M, et al. Improved prognosis of Takayasu arteritis over the past decade-comprehensive analysis of 106 patients[J]. Circ J,2012,76(4):1004-1011.
[9] Perera A H, Youngstein T, Gibbs R G, et al. Optimizing the outcome of vascular intervention for Takayasu arteritis[J]. Br J Surg,2014,101(2):43-50.
[10] Park H S, Do Y S, Park K B, et al. Long term results of endovascular treatment in renal arterial stenosis from Takayasu arteritis: angioplasty versus stent placement[J]. Eur J Radiol,2013,82(11):1913-1918.
[11] Kim Y W, Kim D I, Park Y J, et al. Surgical bypass vs endovascular treatment for patients with supra-aortic arterial occlusive disease due to Takayasu arteritis[J]. J Vasc Surg,2012,55(3):693-700.
[12] Arend W P, Michel B A, Bloch D A, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis[J]. Arthritis Rheum,1990,33(8):1129-1134.
[13] Hata A, Noda M, Moriwaki R, et al. Angiographic findings of Takayasu arteritis: new classification[J]. Int J Cardiol,1996,54 Suppl:S155-S163.
[14] Johnston S L, Lock R J, Gompels M M. Takayasu arteritis: a review[J]. J Clin Pathol,2002,55(7):481-486.
[15] Lee G Y, Jeon P, Do Y S, et al. Comparison of outcomes between endovascular treatment and bypass surgery in Takayasu arteritis[J]. Scand J Rheumatol,2014,43(2):153-161.
[16] Saadoun D, Lambert M, Mirault T, et al. Retrospective analysis of surgery versus endovascular intervention in Takayasu arteritis: a multicenter experience[J]. Circulation,2012,125(6):813-819.
[17] Feng R, Wei X, Zhao Z, et al. Aortorenal bypass with autologous saphenous vein in takayasu arteritis-induced renal artery stenosis[J]. Eur J Vasc Endovasc Surg,2011,42(1):47-53.
[18] Wu X, Duan H Y, Gu Y Q, et al. Surgical treatment of brachiocephalic vessel involvement in Takayasu's arteritis[J]. Chin Med J(Engl),2010,123(9):1122-1126.
[19] 任丽华. 高海拔地区彩超和TCD联合诊断多发大动脉炎1例[J]. 中国煤炭工业医学杂志,2012,15(4):584.
[19] 刘暴,刘昌伟, 陈跃鑫. 胸-腹主动脉型大动脉炎腔内治疗的误区[J]. 临床误诊误治,2014,27(3):7-9.
[21] Agarwal G, Vats H S, Raval A N, et al. Chronic total occlusion and successful drug-eluting stent placement in takayasu arteritis-induced renal artery stenosis[J]. Clin Med Res,2013,11(4):233-236.